newsfilter
← Latest News
PR Newswire·

BioVaxys Expands Cancer Vaccine Platform

BVX-0922 to Target Colorectal Cancer Under Investigator-Sponsored IND VANCOUVER, BC, March 30, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV), (FRA: 5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer